<DOC>
	<DOCNO>NCT01560195</DOCNO>
	<brief_summary>Neutropenia one frequent adverse effect chemotherapy , main factor limit dosage continuation chemotherapy . A newly pegylated rhG-CSF independently develop JIANGSU HENGRUI Medicine Co. , Ltd , China . Phase 1a , 1b phase 2 trial show pegylated rhG-CSF decrease renal clearance , increase plasma half-life , prolong efficacy compare ﬁlgrastim . The purpose study determine safety effectiveness pegylated rhG-CSF prevent neutropenia follow chemotherapy patient advance NSCLC .</brief_summary>
	<brief_title>A Study Pegylated rhG-CSF Support Advanced Non-Small-Cell Lung Cancer ( NSCLC ) Patients Receiving Chemotherapy Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Investigator diagnosis stag III IV NSCLC Age 18 70 year ECOG performance status ≤ 1 Chemotherapy naïve Body weight ≥ 45kg Hemoglobin ≥ 100g/L ; white blood cell ≥ 4.0×109/L ; absolute neutrophil count ≥1.5 × 109/L ; platelet count ≥ 100 × 109/L Alanine transarninase ≤1.5×ULN ; aspartate aminotransferase ≤1.5×ULN ; serum creatinine ≤1.5×ULN ; total bilirubin ≤1.5×ULN History systematic chemotherapy radical radiation therapy Prior bone marrow stem cell transplantation Received systemic antibiotic treatment within 72 h chemotherapy Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>febrile neutropenia</keyword>
	<keyword>chemotherapy</keyword>
</DOC>